Trial Profile
A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients With Geographic Atrophy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jul 2019
Price :
$35
*
At a glance
- Drugs Lampalizumab (Primary)
- Indications Dry age-related macular degeneration
- Focus Therapeutic Use
- Acronyms MAHALO
- Sponsors Genentech
- 04 Dec 2013 New trial record
- 27 Aug 2013 Results were presented at the 31st Annual Meeting of the American Society of Retina Specialists in August 2013.
- 27 Aug 2013 Primary endpoint 'Disease-progression' has been met.